Evidence map›Paper›PMID 30669481›Full record

ArticleInternational journal of molecular sciences2019

Imaging of Metastatic Cancer Cells in Sentinel Lymph Nodes using Affibody Probes and Possibility of a Theranostic Approach.

Makoto Tsuchimochi, Haruka Yamaguchi, Kazuhide Hayama, Yasuo Okada, Tomoyuki Kawase, Takamasa Suzuki, Norio Tsubokawa, Noriaki Wada, Atsushi Ochiai, Satoshi Fujii and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Makoto TsuchimochiEmeritus Professor, The Nippon Dental University, Tokyo, Japan, formerly of the Department of Oral and Maxillofacial Radiology, The Nippon Dental University School of Life Dentistry at Niigata, 1-8 Hamaura-cho, Chuo-ku, Niigata 951-8580, Japan. tsuchimochi@ngt.ndu.ac.jp.
Haruka YamaguchiDepartment of Life Science Dentistry, The Nippon Dental University, 1-9-20 Fujimi, Chiyoda-ku, Tokyo 102-8159, Japan. harukay@ngt.ndu.ac.jp.ORCID 0000-0002-1393-5855
Kazuhide HayamaDepartment of Oral and Maxillofacial Radiology, The Nippon Dental University School of Life Dentistry at Niigata, Niigata 951-8580, Japan. hayama@ngt.ndu.ac.jp.
Yasuo OkadaDepartment of Pathology, The Nippon Dental University School of Life Dentistry at Niigata, Niigata 951-8580, Japan. yokada@ngt.ndu.ac.jp.
Tomoyuki KawaseDivision of Oral Bioengineering, Institute of Medicine and Dentistry, Niigata University, Division of Oral Bioengineering, Department of Tissue Regeneration and Reconstitution, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8541, Japan. kawase@dent.niigata-u.ac.jp.ORCID 0000-0003-4160-396X
Takamasa SuzukiDepartment of Electrical and Electronic Engineering, Faculty of Engineering, Niigata University, Niigata 950-2181, Japan. takamasa@eng.niigata-u.ac.jp.
Norio TsubokawaFaculty of Engineering, Niigata University, Niigata 950-2181, Japan. ntsuboka@eng.niigata-u.ac.jp.
Noriaki WadaDepartment of General Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba 272-8513, Japan. nowada@tdc.ac.jp.
Atsushi OchiaiDivision of Biomarker Discovery, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba 277-8577, Japan. aochiai@east.ncc.go.jp.
Satoshi FujiiDivision of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba 277-8577, Japan. sfujii@east.ncc.go.jp.
Hirofumi FujiiDivision of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba 277-8577, Japan. hifujii@east.ncc.go.jp.ORCID 0000-0001-5470-5151

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accurate detection of lymph node metastases is essential for treatment success in early-stage malignant cancer. Sentinel lymph node (SLN) biopsy is the most effective procedure for detecting small or micrometastases that are undetectable by conventional imaging modalities. To demonstrate a new approach for developing a more efficient SLN biopsy procedure, we reported a two-stage imaging method combining lymphoscintigraphy and near-infrared (NIR) fluorescence imaging to depict metastatic cancer cells in SLNs in vivo. Furthermore, the theranostic potential of the combined procedure was examined by cell culture and xenograft mouse model. Anti-HER2 and anti-epidermal growth factor receptor (EGFR) affibody probes were used for NIR fluorescence imaging. Strong NIR fluorescence signal intensity of the anti-EGFR affibody probe was observed in SAS cells (EGFR positive). Radioactivity in the SLNs was clearly observed in the in vivo studies. High anti-EGFR affibody NIR fluorescence intensity was observed in the metastatic lymph nodes in mice. The addition of the IR700-conjugated anti-EGFR affibody to the culture medium decreased the proliferation of SAS cells. Decreased proliferation was shown in Ki-67 immunohistochemistry in xenograft tumors. Our data suggest that a two-stage combined imaging method using lymphoscintigraphy and affibody probes may offer the direct visualization of metastatic lymph nodes as an easily applied technique in SLN biopsy. Although further animal studies are required to assess the effect of treating lymphatic metastasis in this approach, our study results provide a foundation for the further development of this promising imaging and treatment strategy for earlier lymph node metastasis detection and treatment.

Indexed as

Molecular ImagingMolecular ProbesRecombinant Fusion ProteinsTheranostic NanomedicineAnimalsBiomarkers, TumorCell Line, TumorCells, CulturedFluorescent Antibody TechniqueHumansImmunohistochemistryLymphatic MetastasisMiceNeoplasmsSentinel Lymph NodeSpectroscopy, Near-InfraredBiomarkers, TumorMolecular ProbesRecombinant Fusion ProteinsaffibodyEGFRHER2image-guided surgerymolecular imagingnear-infrared fluorescencephotoimmunotherapyscintigraphysentinel lymph nodetheranostics

Identifiers

PMID30669481
PMCPMC6359136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.